“We are witnessing a revolution in the treatment of hepatitis C virus with powerful molecules capable of curing the infection. There is no question that these treatments that can save millions of lives must be made universally available at an affordable price.” Pr. Françoise Barré-Sinoussi, 2008 (...) More
The World Health Organization (WHO) has referred to hepatitis C as a “viral time bomb”. In 2010, the 63rd World Health Assembly (WHA) adopted the first resolution on viral hepatitis; a new resolution will be presented
at this Assembly. More
On September 14, 2014, Gilead announced a voluntary license (VL) agreement with seven Indian drug manufacturers . The agreement will allow these companies to produce and sell generic versions of sofosbuvir (Sovaldi©) and ledipasvir , Gilead’s direct-acting antiviral (DAA) medications for (...) More
European Patent Office (EPO) has taken its decision following Doctors of the World - Médecins du Monde (MdM) patent opposition on Gilead Sciences’ Sofosbuvir. MdM applauds EPO’s decision to revoke partially the patent.
MdM has filled an opposition on the patent granted to Gilead Sciences for (...) More